Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Trump Planning on Executive Order to Further Cut Medicare Drug Prices - Report
Lilly Benefits as Judge Upholds FDA Removing Zepbound From Shortages List
Gilead to Invest About $32B in U.S. Manufacturing Through 2030
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Cuts 2025 Outlook. But Why Are Its Shares Rising?
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Eli Lilly Stock Is Sliding Tuesday: What's Going On?
Trump Administration Cancels Meeting With FDA Workers Union - Report
Eli Lilly in Licensing Pact With Alchemab for ALS Program
'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post
Healthcare Sector Flexes Earnings Muscle, but Top-line Cracks Show
UBS Maintains Buy on Eli Lilly, Lowers Price Target to $1050
Eli Lilly Analyst Ratings
Novo Nordisk Says Oral Version of Wegovy Accepted for FDA Review
Cigna to Launch Specialized GLP-1 Pharmacy Next Month
Eli Lilly's Options Frenzy: What You Need to Know
What happened? Eli Lilly and Co's Q1 revenue surged by 45%, but the stock price plummeted more than 10% during trading.
In the first quarter, Eli Lilly and Co's weight loss drug Zepbound saw sales increase more than threefold, while the annual EPS guidance was lowered by over 7% due to acquisition-related expenses, with the annual revenue guidance remaining unchanged, but only reflecting the impact of Trump tariffs as of early May. The chain pharmacy giant CVX has decided to include Novo-Nordisk A/S's Wegovy as the preferred option in its main prescription drug catalog starting in July, while Zepbound was not included, with the CEO of Eli Lilly and Co calling it "a step backward."
WHO Set to Back Use of Weight Loss Drugs Such as Zepbound, Wegovy - Report